Drug Security Forum

The Medicine Provision System: Improving Availability

02 Jun , 14:30–16:00
Drug Security Forum
Panel Session
Pavilion G, conference hall G6

The drug assistance system for patients entitled to government support is currently lacking, with regional inequality in drug supply, a lack of brand choice, inappropriate expenditure of monetary benefits, duplication of benefit registers, and monitoring of treatment effectiveness all remaining problem areas. A development strategy for the pharma industry that is based on drug security principles must take into account the evolution of the drug supply system. Any efforts to modernize the existing system for benefit-entitled citizens and other groups of patients with serious diseases must be built on principles of improving its intrinsic tools and its ability to be integrated into a system featuring any model of drug supply, be it drug reimbursement, elements of co-pay, or anything else. The strategy must enable more citizens to be able to count on social preferences, expand the outpatient list of drugs, increase the preventive role of the outpatient sector, and stimulate investment in the pharma industry. What assumptions and objective factors form the basis of the current drug supply system? What tools will help better supply drugs to patients qualifying for benefits? What criteria define economic models of drug reimbursement that are most acceptable to Russia, and what models of full or partial reimbursement of drug costs may be the most effective? Is the Russian Federation ready for universal outpatient drug supply?

Aleksandr Petrov, Head of the Subcommittee on Circulation of Medicines, Development of the Pharmaceutical and Medical Industry, Committee of the State Duma of the Federal Assembly of the Russian Federation on Health Protection

Natasha Azzopardi-Muscat, Director, Division of Country Health Policies and Systems, Regional Office for Europe, World Health Organization (online)
Elena Astapenko, Director, Department of Pharmaceutical Provision and Regulation of the Circulation of Medical Devices, Ministry of Health of the Russian Federation
Alisa Dzhangiryants, Director of Market Access and Pricing, Bristol-Myers Squibb (online)
Gilles Carbonnier, Vice President, International Committee of the Red Cross
Natalia Kolerova, President, Novartis Group in Russia; General Manager, Oncology Department, Russia, Ukraine and CIS, Novartis AG
Timofey Nizhegorodtsev, Deputy Head, Federal Antimonopoly Service of the Russian Federation
Ekaterina Pogodina, Director General, Managing Director of Janssen Pharmaceutical Companies, Johnson & Johnson Russia & CIS
Elena Chernyakova, Chairman, Federal Compulsory Medical Insurance Fund

Front row participant
Dmitry Kudrumov, First Deputy Chairman of the Government of Kirov Region